| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 4 Feb 2026 | 30 Jan 2026 |
| Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2026 inter alia to consider and approve Unaudited financial result for the Third Quarter ended on 31 December 2025 along with the Auditors Limited Review Report. The Board Meeting to be held on 07/02/2026 has been revised to 04/02/2026 The Board Meeting to be held on 07/02/2026 has been revised to 04/02/2026 Unaudited Financial Results for the quarter ended December 2025 (As Per BSE Announcement Dated on: 04/02/2026) | ||
| Board Meeting | 28 Jan 2026 | 28 Jan 2026 |
| Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation, 2015. | ||
| Board Meeting | 30 Dec 2025 | 30 Dec 2025 |
| Board Meeting Outcome for Outcome Of Meeting Of Board Of Directors Held On December 30, 2025. | ||
| Board Meeting | 29 Nov 2025 | 29 Nov 2025 |
| Regulation 30 the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation, 2015. | ||
| Board Meeting | 13 Nov 2025 | 31 Oct 2025 |
| Quarterly Results Un-Audited Financial Results of the Company for the Second Quarter and Half Year ended September 30, 2025, along with the Auditors Limited Review Reports in accordance with the provisions of Regulation 33 of the SEBI Listing Regulations. (As Per BSE Announcement Dated on 13.11.2025) | ||
| Board Meeting | 3 Oct 2025 | 22 Sep 2025 |
| Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/10/2025 inter alia to consider and approve As attached. Revised outcome - pursuant to typographical error founded in the outcome submitted on october 03, 2025. (As Per BSE Announcement Dated on 04.10.2025) | ||
| Board Meeting | 8 Sep 2025 | 8 Sep 2025 |
| Revision in date of AGM | ||
| Board Meeting | 30 Aug 2025 | 30 Aug 2025 |
| As attached | ||
| Board Meeting | 13 Aug 2025 | 31 Jul 2025 |
| Quarterly Results Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 ,inter alia, to consider and approve 1. Unaudited financial result for the quarter ended on June 30, 2025 along with the Limited Review Report of the Auditor pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. 2. Any other business with the permission of Chairman. Un-Audited Financial Results of the Company for the First Quarter ended June 30, 2025, along with the Auditors Limited Review Reports in accordance with the provisions of Regulation 33 of the SEBI Listing Regulations. (As Per BSE Announcement Dated on: 13.08.2025) | ||
| Board Meeting | 4 Jun 2025 | 31 May 2025 |
| Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/06/2025 inter alia to consider and approve To Consider & declare final dividend on the paid-up equity share capital of the Company for the Financial Year 2024-2025 Outcome of the meeting of the Board of Directors held on Wednesday, June 04, 2025 The 1/- each Board fully recommended a Final Dividend of Rs. 0.01/- (1%) per equity share of Rs. This paid (subject to deduction of tax, if any) for the financial year 2024-25, General shall be paid subject to the approval of the shareholders at the ensuing Annual Meeting of the Company. (As Per BSE Announcement Dated on 04.06.2025) | ||
| Board Meeting | 29 May 2025 | 16 May 2025 |
| Audited Results Outcome of the meeting of the Board of Directors held on Thursday May 29, 2025 Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2025 ,inter alia, to consider and approve Audited financial result for the quarter and financial year ended on 31st March, 2025 along with the Auditors Report and Certificate for unmodified opinion Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (As Per BSE Announcement dated on 16.05.2025) Audited Financial Statements for the quarter and year ended on March 31, 2025 (As per BSE Announcement Dated on 29/05/2025) | ||
| Board Meeting | 29 Mar 2025 | 29 Mar 2025 |
| Intimation of change in Secretarial Auditor of the company | ||
| Board Meeting | 26 Mar 2025 | 26 Mar 2025 |
| Outcome of the meeting of Independent directors held on today to consider the agendas as attached. | ||
The contract, valued at ₹24.06 crore, includes the complete scope of supply along with packing, forwarding, insurance and delivery right up to the consignee site in Afghanistan.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
